Server:Microsoft-IIS/7.5...
X-Powered-By:ASP.NET
The main IP address: 5.44.24.16,Your server United States,New York City ISP:Coloni Limited TLD:ch CountryCode:US
The description :biopartners is dedicated to improving quality of life through significant advancements in patient care. we are dynamic and growing biopharmaceutical company...
This report updates in 30-Jul-2018
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host biopartners.ch. Currently, hosted in United States and its service provider is Coloni Limited .
Latitude: | 40.71427154541 |
Longitude: | -74.005966186523 |
Country: | United States (US) |
City: | New York City |
Region: | New York |
ISP: | Coloni Limited |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/7.5 containing the details of what the browser wants and will accept back from the web server.
Content-Length: | 3638 |
Content-Encoding: | gzip |
Accept-Ranges: | bytes |
X-Powered-By: | ASP.NET |
Vary: | Accept-Encoding |
Server: | Microsoft-IIS/7.5 |
Last-Modified: | Wed, 04 Feb 2015 12:41:21 GMT |
ETag: | "806ec4e07740d01:0" |
Date: | Mon, 30 Jul 2018 07:43:03 GMT |
Content-Type: | text/html |
soa: | ns1.first365.net. hostmaster.firstframe.net. 2018041304 1200 600 172800 3600 |
txt: | "v=spf1 a mx include:spf.protection.outlook.com ip4:91.200.32.11 ip4:217.149.240.5 ip4:217.149.240.6 ip4:217.149.240.7 ip4:195.248.72.12 -all" "MS=ms99992771" |
ns: | ns2.first365.net. ns1.first365.net. |
ipv4: | IP:5.44.24.16 ASN:13768 OWNER:COGECO-PEER1 - Cogeco Peer 1, CA Country:GB |
mx: | MX preference = 0, mail exchanger = biopartners-ch.mail.protection.outlook.com. |
biopartners site map | privacy | legal home about us therapeutic areas partners news careers contact search developing biologics, delivering patient care. biopartners is dedicated to improving quality of life through significant advancements in patient care. we are a dynamic and growing biopharmaceutical company, leading the development of biopharmaceutical products in the fields of endocrinology, multiple sclerosis and virology. our comprehensive product portfolio consists of first-generation biopharmaceuticals with innovative-formulations or novel delivery systems. a pioneer in biopharmaceuticals we are the first company to receive a marketing authorisation in the eu, norway and iceland for a prolonged-release formulation of recombinant human growth hormone (rhgh) which will cut the number of self-administered injections from once-a-day to once-a-week - a major breakthrough in rhgh treatment. a pioneer in biopharmaceuticals we are the first company to receive a marketing authorisation in the eu, norway and iceland for a prolonged-release formulation of recombinant human growth hormone (rhgh) which will cut the number of self-administered injections from once-a-day to once-a-week - a major breakthrough in rhgh treatment. latest news 5th aug 2013 somatropin biopartners receives marketing authorisation in the eu, norway and iceland 31st may 2013 positive chmp opinion for once-weekly somatropin biopartners 18th oct 2012 twenty-four months efficacy and safety of lb03002, a new sustained release formulation of rhgh, in children with ghd: extension of a phase iii randomised multicentre study are presented at the growth hormone and igf-1 research society in munich, germany. 22nd sep 2012 metabolic effects of lb03002, a sustained release formulation of rhgh, in children with gh deficiency are presented at espe 2012 in leipzig, germany. 20th sep 2012 the pter et al. paper (jcem 2012, 97(2):400-407) is featured in the 2012 yearbook of endocrinology. the reviewers state that the data look promising, showing a growth response and safety profile comparable to daily rhgh. copyright biopartners 2013. all rights reserved. | designed by digits last updated: september 2013
http://www.biopartners.ch/mainnews976.htm
http://www.biopartners.ch/press_release.htm
http://www.biopartners.ch/therapeutic/index.htm
http://www.biopartners.ch/contact/index.htm
http://www.biopartners.ch/sitemap.htm
http://www.biopartners.ch/aboutus/index.htm
http://www.biopartners.ch/mainnews938.htm
http://www.biopartners.ch/privacy/index.htm
http://www.biopartners.ch/mainnews966.htm
http://www.biopartners.ch/mainnews973.htm
http://www.biopartners.ch/partners/index.htm
http://www.biopartners.ch/accessibility/index.htm
http://www.biopartners.ch/index.htm
http://www.biopartners.ch/mainnews937.htm
http://www.biopartners.ch/careers/index.htm
digits.co.uk
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
The number of requests per client per time interval is
restricted. You have exceeded this limit.
Please wait a moment and try again.
REFERRER http://www.nic.ch
REGISTRAR SWITCH Domain Name Registration
SERVERS
SERVER ch.whois-servers.net
ARGS biopartners.ch
PORT 43
TYPE domain
REGISTERED no
DOMAIN
NAME biopartners.ch
NSERVER
NS1.FIRST365.NET 185.75.154.83
NS2.FIRST365.NET 185.75.155.83
The following list shows you to spelling mistakes possible of the internet users for the website searched .